title: Modulation of Ras/ERK and Phosphoinositide Signaling by Long-Chain n-3 PUFA in Breast Cancer and Their Potential Complementary Role in Combination with Targeted Drugs.
abstract: A potential complementary role of the dietary long-chain n-3 polyunsaturated fatty acids (LCn-3 PUFA) in combination with innovative mono-targeted therapies has recently been proposed. These compounds are thought to act pleiotropically to prevent the development and progression of a variety of cancers, including breast cancer. We hereinafter critically analyze the reports investigating the ability of LCn-3 PUFA to modulate the Ras/ERK and the phosphoinositide survival signaling pathways often aberrantly activated in breast cancer and representing the main targets of innovative therapies. The in vitro or in vivo animal and human interventional studies published up to January 2017 investigating the effects of LCn-3 PUFA on these pathways in normal and cancerous breast cells or tissues were identified through a systematic search of literature in the PubMed database. We found that, in most cases, both the in vitro and in vivo studies demonstrated the ability of LCn-3 PUFA to inhibit the activation of these pro-survival pathways. Altogether, the analyzed results strongly suggest a potential role of LCn-3 PUFA as complementary agents in combination with mono-targeted therapies. Moreover, the results indicate the need for further in vitro and human interventional studies designed to unequivocally prove the potential adjuvant role of these fatty acids.
authors.affiliation: Institute of General Pathology, Università Cattolica del S. Cuore, Largo F. Vito 1, 00168 Rome, Italy. simona.serini@unicatt.it.
authors.forename: Simona
authors.initials: S
authors.lastname: Serini
authors.affiliation: Institute of General Pathology, Università Cattolica del S. Cuore, Largo F. Vito 1, 00168 Rome, Italy. gabriella.calviello@unicatt.it.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Calviello
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy*; D016208:Databases, Factual; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D005260:Female; D006801:Humans; D020935:MAP Kinase Signaling System; D010716:Phosphatidylinositols / Q000378:metabolism*; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D015525:Fatty Acids, Omega-3; D010716:Phosphatidylinositols; D051057:Proto-Oncogene Proteins c-akt
keywords: ERK pathway; animal studies; breast cancer; cytotoxic effect; docosahexaenoic acid; eicosapentaenoic acid; human studies; in vitro studies; omega-3 PUFA; phosphoinositide pathway